导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.76% | 2741/4773 |
| 近一周 | -0.77% | 258/5462 |
| 近一月 | 1.17% | 416/5421 |
| 近一季 | 1.78% | 513/5209 |
| 近半年 | -2.66% | 1978/4920 |
| 近一年 | 0.22% | 2615/4366 |
| 近两年 | 25.31% | 2487/2954 |
| 近三年 | 26.61% | 1198/2253 |
| 成立以来 | 72.88% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.95% 3470/4961 |
-3.58% 3464/5312 |
- - |
- - |
| 2025 | 4.70% 3036/4813 |
-4.50% 3186/3635 |
5.43% 589/4076 |
1.24% 3882/4524 |
2.71% 874/4813 |
| 2024 | 31.83% 92/3463 |
8.45% 184/2808 |
6.07% 183/3014 |
12.40% 2356/3129 |
1.96% 998/3463 |
| 2023 | -0.11% 436/2656 |
3.66% 1152/2280 |
0.71% 283/2385 |
1.67% 293/2515 |
-5.88% 1540/2655 |
| 2022 | -7.89% 150/2207 |
-5.59% 195/1919 |
1.46% 1476/2016 |
-7.84% 148/2113 |
4.34% 558/2208 |
| 2021 | 1.62% 661/1822 |
3.09% 197/1255 |
-0.63% 1145/1330 |
-0.38% 493/1466 |
-0.42% 1236/1822 |
| 2020 | 8.28% 857/1250 |
-12.91% 905/1028 |
4.60% 905/1067 |
11.44% 448/1164 |
6.66% 750/1184 |
| 2019 | 18.16% 680/1092 |
17.63% 652/754 |
-1.31% 304/804 |
-2.84% 715/850 |
4.76% 783/918 |
| 2018 | -14.20% 96/834 |
- - |
- - |
- - |
-8.32% 87/691 |
| 2017 | 20.35% 186/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.96% 233/605 |
- - |
- - |
- - |
- - |
| 2015 | -6.19% 278/575 |
- - |
- - |
- - |
- - |
| 2014 | 80.35% 8/237 |
- - |
- - |
- - |
- - |
| 2013 | -13.72% 170/186 |
- - |
- - |
- - |
- - |
| 2012 | 10.21% 40/140 |
- - |
- - |
- - |
- - |
| 2011 | -19.79% 37/102 |
- - |
- - |
- - |
- - |
| 2010 | -23.37% 55/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 工银上证央企ETF VS. 长安沪深300非周期A(740101) |